OgCelix provides a comprehensive portfolio of organoid products designed to advance both basic and translational research. Our 3D-ready organoid models, derived from healthy tissue, Induced Pluripotent Stem Cells (iPSCs), patient samples, and selected animal sources, covering a wide range of organs including liver, lung, brain, colon, pancreas, and breast. These models recapitulate key aspects of native tissue architecture,maintain key genomic features over passages under defined conditions, and patient-derived models retain disease-relevant phenotype, making them powerful systems for studying human development, disease mechanisms, drug response, and precision medicine applications.
To support reliable organoid establishment and long-term growth, we supply a full range of media and reagents, including culture media, basement membranes matrix, growth factors, and culture plates, all support robust expansion and controlled differentiation. Complementing these are organoid-validated antibodies antibodies targeting key lineage, immune, and tumor-associated markers, rigorously validated across applications such as IHC, IF, WB, and flow cytometry to provide high-confidence results.
Beyond models and reagents, OgCelix also delivers a range of services that broaden the possibilities of organoid research. All our products and services are supported by stringent quality control measures to ensure consistency, reliability, and scientific rigor across every stage of research.
With a portfolio that unites organoid models, culture systems, antibodies, and advanced services, OgCelix equips researchers with the tools and confidence to generate reproducible, clinically relevant insights and to accelerate the journey from discovery to therapeutic innovation.
Organoid models derived from ASCs, iPSCs, or tissues, including both healthy and disease-specific samples.
Organoids maintain native tissue architecture and functional properties that closely mimic in vivo conditions.
Demonstrated genetic and phenotypic stability across extended culture periods, ensuring reproducibility.
Showing all 378 results
19.8 kDa
Less than 1.0 EU per μg by the LAL method / rFC method.
E. coli cells
13.1 kDa
Less than 0.01 EU per μg by the LAL method / rFC method.
CHO cells
13.1 kDa
Less than 0.01 EU per μg by the LAL method / rFC method.
CHO cells
13.2 kDa
Less than 0.05 EU per μg by the LAL method / rFC method.
E. coli cells
13.2 kDa
Less than 0.05 EU per μg by the LAL method / rFC method.
E. coli cells
34.1 kDa
Less than 1.0 EU per μg by the LAL method / rFC method.
Human 293 cells (HEK293)
13.1 kDa
Less than 10.0 EU per μg by the LAL method / rFC method.
Human 293 cells (HEK293)
9.5 kDa
Less than 0.1 EU per μg by the LAL method / rFC method.
Human 293 cells (HEK293)
34.1 kDa
Less than 1.0 EU per μg by the LAL method / rFC method.
Human 293 cells (HEK293)
Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.
Let's build the future of translational research together.
Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.
Let's build the future of translational research together.